Literature DB >> 12387655

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

Mariska Klerk1, Petra Verhoef, Robert Clarke, Henk J Blom, Frans J Kok, Evert G Schouten.   

Abstract

CONTEXT: In observational studies, individuals with elevated levels of plasma homocysteine tend to have moderately increased risk of coronary heart disease (CHD). The MTHFR 677C-->T polymorphism is a genetic alteration in an enzyme involved in folate metabolism that causes elevated homocysteine concentrations, but its relevance to risk of CHD is uncertain.
OBJECTIVE: To assess the relation of MTHFR 677C-->T polymorphism and risk of CHD by conducting a meta-analysis of individual participant data from all case-control observational studies with data on this polymorphism and risk of CHD. DATA SOURCES: Studies were identified by searches of the electronic literature (MEDLINE and Current Contents) for relevant reports published before June 2001 (using the search terms MTHFR and coronary heart disease), hand searches of reference lists of original studies and review articles (including meta-analyses) on this topic, and contact with investigators in the field. STUDY SELECTION: Studies were included if they had data on the MTHFR 677C-->T genotype and a case-control design (retrospective or nested case-control) and involved CHD as an end point. Data were obtained from 40 (34 published and 6 unpublished) observational studies involving a total of 11 162 cases and 12 758 controls. DATA EXTRACTION: Data were collected on MTHFR 677C-->T genotype, case-control status, and plasma levels of homocysteine, folate, and other cardiovascular risk factors. Data were checked for consistency with the published article or with information provided by the investigators and converted into a standard format for incorporation into a central database. Combined odds ratios (ORs) for the association between the MTHFR 677C-->T polymorphism and CHD were assessed by logistic regression. DATA SYNTHESIS: Individuals with the MTHFR 677 TT genotype had a 16% (OR, 1.16; 95% confidence interval [CI], 1.05-1.28) higher odds of CHD compared with individuals with the CC genotype. There was significant heterogeneity between the results obtained in European populations (OR, 1.14; 95% CI, 1.01-1.28) compared with North American populations (OR, 0.87; 95% CI, 0.73-1.05), which might largely be explained by interaction between the MTHFR 677C-->T polymorphism and folate status.
CONCLUSIONS: Individuals with the MTHFR 677 TT genotype had a significantly higher risk of CHD, particularly in the setting of low folate status. These results support the hypothesis that impaired folate metabolism, resulting in high homocysteine levels, is causally related to increased risk of CHD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12387655     DOI: 10.1001/jama.288.16.2023

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  192 in total

1.  Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis.

Authors:  A Pezzini; M Grassi; E Del Zotto; D Assanelli; S Archetti; R Negrini; L Caimi; A Padovani
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04-19       Impact factor: 10.154

2.  Folate and risk of cardiovascular disease. Study results were misinterpreted.

Authors:  David S Wald; Malcolm Law; Joan Morris; Nicholas J Wald
Journal:  BMJ       Date:  2003-05-10

3.  Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

Authors:  Vicki L Ellingrod; Stephan F Taylor; Gregory Dalack; Tyler B Grove; Michael J Bly; Robert D Brook; Sebastian K Zöllner; Rodica Pop-Busui
Journal:  J Clin Psychopharmacol       Date:  2012-04       Impact factor: 3.153

4.  Genetics of cardiovascular disease.

Authors:  Rosanna Abbate; Elena Sticchi; Cinzia Fatini
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

5.  Folate network genetic variation predicts cardiovascular disease risk in non-Hispanic white males.

Authors:  Susan M Wernimont; Andrew G Clark; Patrick J Stover; Martin T Wells; Augusto A Litonjua; Scott T Weiss; J Michael Gaziano; Pantel S Vokonas; Katherine L Tucker; Patricia A Cassano
Journal:  J Nutr       Date:  2012-05-30       Impact factor: 4.798

6.  Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders.

Authors:  Tyler Grove; Stephan Taylor; Gregory Dalack; Vicki Ellingrod
Journal:  Schizophr Res       Date:  2015-02-23       Impact factor: 4.939

7.  Assessment of tailor-made prevention of atherosclerosis with folic acid supplementation: randomized, double-blind, placebo-controlled trials in each MTHFR C677T genotype.

Authors:  Koichi Miyaki; Mitsuru Murata; Haruhito Kikuchi; Izumi Takei; Takeo Nakayama; Kiyoaki Watanabe; Kazuyuki Omae
Journal:  J Hum Genet       Date:  2005-05-14       Impact factor: 3.172

8.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

9.  The association of the MTHFR c.1625A>C genetic variant with the risk of congenital heart diseases in the Chinese.

Authors:  Yuting Wang; Lei Sun; Weina Du; Shuang Song; Shuo Wang; Weiju Jiang; Tianchu Huang; Hui Li
Journal:  Genet Test Mol Biomarkers       Date:  2015-01

10.  Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).

Authors:  Karen L Margolis; Kay Dunn; Lara M Simpson; Charles E Ford; Jeff D Williamson; David J Gordon; Paula T Einhorn; Jeffrey L Probstfield
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.